Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shane Reynolds

Podiatrist Norwalk, CT Doctor of Podiatric Medicine

NPI 1780079269 CMS profile 6572785

488 Main Ave, Norwalk, CT 06851

Open in the dashboard

General payments

$13,511

153 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shane Reynolds of Norwalk, CT is reported in the CMS Open Payments database as having received $13,511 across 153 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $365 7
2024 General $331 8
2023 General $2,388 11
2022 General $2,593 19
2021 General $2,235 33
2020 General $1,065 24
2019 General $4,535 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shane Reynolds
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Shane Reynolds were reported at $365. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Shane Reynolds Podiatrist median Middle half National median
2019 $4,535 $196 $72–$601 $163
2020 $1,065 $118 $38–$335 $114
2021 $2,235 $169 $57–$573 $132
2022 $2,593 $220 $74–$782 $149
2023 $2,388 $208 $71–$635 $160
2024 $331 $237 $87–$681 $164
2025 $365 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Gramercy Extremity Orthopedics LLC $2,197 3 payments
  2. Orthofix Medical, Inc. $2,033 21 payments
  3. International Life Sciences $1,918 1 payment
  4. Gotham Surgical Solutions & Devices, Inc. $1,586 3 payments
  5. Smith+Nephew, Inc. $1,269 37 payments
  6. Celularity, Inc. $961 13 payments
  7. Stryker Corporation $640 11 payments
  8. Musculoskeletal Transplant Foundation Inc. $532 4 payments
  9. Organogenesis Inc. $374 10 payments
  10. Treace Medical Concepts, Inc. $326 5 payments
  11. Other $1,676 45 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,932 138 payments
  2. Consulting Fee $2,063 2 payments
  3. Travel and Lodging $2,013 12 payments
  4. Education $1,503 1 payment
Products named General payments · program years 2019–2025
  1. TL-HEX $1,043 11 payments
  2. TrueLok Ring Fixation System $1,043 11 payments
  3. TrueLok $896 9 payments
  4. Biovance $859 10 payments
  5. Distal Fibula Plating System $563 1 payment
  6. GRAFIX PL $414 8 payments
  7. STRAVIX Extremities & Limb Restoration $375 7 payments
  8. Puraply $284 6 payments
  9. Stravix Other Advanced Wound Management $279 3 payments
  10. COLLAGENASE SANTYL $208 5 payments
  11. Other $4,991 129 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

70

Median for Podiatry: 160

Drug cost

$665

Median for Podiatry: $2,368

Branded share of claims

0%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fluconazole Generic 32 $293
Gabapentin Generic 20 $250
Methylprednisolone Generic 18 $122

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$37,413

Medicare's payments for the services billed

Medicare patients

187

Average age 74

Services billed

840

102 women, 85 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 49%
Diabetes 38%
Ischemic heart disease 33%
Chronic kidney disease 28%
Atrial fibrillation 24%
Depression 22%
Heart failure 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUZYRA
  • Paratek Pharmaceuticals, Inc. $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

153 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record